This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribera, E.
Right arrow Articles by Pahissa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribera, E.
Right arrow Articles by Pahissa, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3238-3241, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3238-3241.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Rifampin Reduces Concentrations of Trimethoprim and Sulfamethoxazole in Serum in Human Immunodeficiency Virus-Infected Patients

Esteban Ribera,1,* Leonor Pou,2 Antoni Fernandez-Sola,1 Francisco Campos,2 Rosa M. Lopez,2 Imma Ocaña,1 Isabel Ruiz,1 and Albert Pahissa1

Infectious Disease Service1 and Clinical Biochemistry Service,2 Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain

Received 22 December 2000/Returned for modification 5 June 2001/Accepted 12 August 2001

To determine whether rifampin reduces concentrations of trimethoprim (TMP) and sulfamethoxazole (SMX) in serum of human immunodeficiency virus (HIV)-infected persons, levels of these agents were determined by high-performance liquid chromatography before and after more than 12 days of standard antituberculosis treatment for 10 patients who had been taking one double-strength tablet of co-trimoxazole once daily for more than 1 month. Statistically significant, 47 and 23% decreases in TMP and SMX mean areas under the concentration-time curve from 0 to 24 h (AUC0-24), respectively, were observed after administration of rifampin. N-Acetyl-SMX profiles without and with rifampin were similar. The steady-state AUC0-24 metabolite/parent drug ratio increased by 32% with rifampin administration. Our study shows that rifampin reduces profiles of TMP and SMX in serum of HIV-infected patients.

* Corresponding author. Mailing address: Servicio de Enfermedades Infecciosas, Hospital Vall d'Hebron, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain. Phone: 34 9327 46090. Fax: 34 9327 46057. E-mail: eribera{at}hg.vhebron.es.

Antimicrobial Agents and Chemotherapy, November 2001, p. 3238-3241, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3238-3241.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Subramanian, S., Roberts, C. L., Hart, C. A., Martin, H. M., Edwards, S. W., Rhodes, J. M., Campbell, B. J. (2008). Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. Antimicrob. Agents Chemother. 52: 427-434 [Abstract] [Full Text]  
  • Martinez-Lacasa, J., Cabellos, C., Martos, A., Fernandez, A., Tubau, F., Viladrich, P. F., Linares, J., Gudiol, F. (2002). Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 49: 507-513 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»